North America Scleroderma Therapeutics Market – Industry Trends and Forecast to 2026

SUBSCRIBE FOR UPDATED REPORTS

Get great contents delivered straight to your inbox everyday, just a click away, Sign Up Now.
Name
Email
US : +1-888-387-2818
UK : +44 208 089 1725

North America Scleroderma Therapeutics Market – Industry Trends and Forecast to 2026

North America
Publish Reports
North America Scleroderma Therapeutics Market
  • No of pages :
    350
  • No of Figures:
    22
  • No of Tables:
    52
  • Report Type:
    Publish
  • Category:

North America Scleroderma Therapeutics Market By Type (Localized Scleroderma, Systemic Scleroderma), Treatment Type (Drug Treatment, Surgical Treatment, Therapy), End User (Hospital, Specialty Clinics, Homecare Settings, Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2026 – Industry Trends and Forecast to 2026

Scleroderma is an auto-immune disease of unknown etiology and is characterized by fibrosis and microvascular injury in affected organs. In this disease, Raynaud’s phenomenon is an initial symptom which shows in puffiness of fingers. There are two types of scleroderma- localized scleroderma and limited scleroderma. Localized sclerosis shows plaques of fibrotic skin and subcutaneous tissue which further occurs as linear fibrotic bands on extremities such as skin and deeper tissue. There are two types of localized scleroderma which are morphea and linear scleroderma.

As per the studies carried out by researchers, it has been found that the disease occurs due to the changes in certain parameter in environment or changes in certain gene in human. The symptoms involves in this disease is abnormalities on the skin, painful joints, morning stiffness, fatigue, and/or weight loss and many others.

There is no drug or treatment available to treat scleroderma but there are certain drugs available which can be used in treating the disease associated to scleroderma such as kidney disease, Heartburn (acid reflux), Raynaud’s phenomenon and others. Some of them are aspirin, naproxen, ibuprofen and many others.

North America scleroderma therapeutics market is projected to register a healthy CAGR of 5.7% in the forecast period of 2019 to 2026

Segmentation: North America Scleroderma Therapeutics Market

North America scleroderma therapeutics market is segmented into three notable segments such as type, treatment type, end user.

  • On the basis of type, the market is segmented into localized scleroderma and systemic scleroderma. Localized scleroderma is further segmented into morphea and linear scleroderma. Systemic scleroderma is further segmented into limited cutaneous systemic sclerosis or CREST syndrome and diffuse systemic sclerosis. In 2019 systemic scleroderma segment is growing at the highest CAGR in the forecast period of 2019 to 2026.
  • On the basis of treatment type, the market is segmented into drug treatment, surgery treatment and therapy. Drug treatment is further segmented into anti-inflammatory drugs, immunosuppressants, corticosteroids, H2 blockers, chelating agents, proton pump inhibitors, PDE5 inhibitors, prostacyclin analogues, ACE inhibitors, endothelin receptor antagonists, calcium channel blockers and others. Therapy is further segmented into physical therapy, ultraviolet light therapy and others. In 2019, anti-inflammatory drugs segment is growing at the highest CAGR in the forecast period of 2019 to 2026.
  • On the basis of end user, the market is segmented into hospital, speciality clinics, homecare settings and others. In 2019, hospital segment is growing at the highest CAGR in the forecast period of 2019 to 2026.

Competitive Analysis: North America Scleroderma Therapeutics Market

Some of the prominent participants operating in this market are Argentis Pharmaceuticals, LLC., F. Hoffmann-La Roche Ltd, AbbVie Inc., Pfizer Inc., Sanofi, ALLERGAN, viDA Therapeutics Inc., Novartis AG, Active Biotech AB., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Johnson & Johnson Services, Inc., AstraZeneca, Daval International Limited and others.

Research Methodology: North America Scleroderma Therapeutics Market

Primary Respondents: Key Opinion Leaders (KOL’s): Manufacturer, Healthcare Professionals, Doctors, Nurses, Medical practitioners. Industry Participants: CEO’s, V.P.’s, Marketing/Product Managers, Market Intelligence Managers and, National Sales Managers.

Choose Licence Type

Enterprise, Single User

TABLE OF CONTENTS NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED
2.2 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET : GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 DBMR MARKET POSITION GRID
2.8 TIME LINE
2.9 MULTIVARIATE MODELLING
2.10 SECONDARY SOURCES
2.11 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.1.1 RISING CASES OF SCLERODERMA
3.1.2 INCREASING ACCESS TO MEDICAL INSURANCE IN THE U.S.
3.1.3 INCREASING MERGER AND ACQUISITIONS

3.2 RESTRAINTS

3.2.1 LACK OF CURATIVE TREATMENT
3.2.2 STRINGENT REGULATIONS
3.2.3 COUNTERFEIT PRODUCTS

3.3 OPPORTUNITY

3.3.1 UNMET PATIENT NEEDS IN SYSTEMIC SCLEROSIS

3.4 CHALLENGE

3.4.1 SIDE EFFECTS OF DRUGS

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 PIPELINE PRODUCTS

7 EPIDEMIOLOGY

7.1 HISTORY OF SCLERODERMA:
7.2 RECENT INCIDENCE AND PREVALENCE:
7.3 CAUSE OF SCLERODERMA:
7.4 SYMPTOMS OF SCLERODERMA:
7.5 MANAGING SCLERODERMA:

8 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY TYPE

8.1 OVERVIEW
8.2 SYSTEMIC SCLERODERMA

8.2.1 LIMITED CUTANEOUS SYSTEMIC SCLEROSIS OR CREST SYNDROME
8.2.2 DIFFUSE SYSTEMIC SCLEROSIS

8.3 LOCALIZED SCLERODERMA

8.3.1 MORPHEA
8.3.2 LINEAR SCLERODERMA

9 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE

9.1 OVERVIEW
9.2 DRUG TREATMENT

9.2.1 DRUG TREATMENT, BY TYPE

9.2.1.1 ANTI-INFLAMMATORY DRUGS
9.2.1.2 IMMUNOSUPPRESSANTS
9.2.1.3 CORTICOSTEROIDS
9.2.1.4 PROTON PUMP INHIBITORS
9.2.1.5 CALCIUM CHANNEL BLOCKERS
9.2.1.6 ACE INHIBITORS
9.2.1.7 H2 BLOCKERS
9.2.1.8 PDE5 INHIBITORS
9.2.1.9 PROSTACYCLIN ANALOGUES
9.2.1.10 ENDOTHELIN RECEPTOR ANTAGONISTS
9.2.1.11 CHELATING AGENTS (EDATHAMIL DISODIUM)
9.2.1.12 OTHERS

9.2.2 DRUG TREATMENT, BY DISTRIBUTION CHANNEL

9.2.2.1 HOSPITAL PHARMACY
9.2.2.2 RETAIL PHARMACY
9.2.2.3 ONLINE PHARMACY
9.2.2.4 OTHERS

9.3 SURGICAL TREATMENT
9.4 THERAPY

9.4.1 ULTRAVIOLET LIGHT THERAPY
9.4.2 PHYSICAL THERAPY
9.4.3 OTHERS

10 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY END USER

10.1 OVERVIEW
10.2 HOSPITAL
10.3 SPECIALTY CLINICS
10.4 HOMECARE SETTINGS
10.5 OTHERS

11 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY GEOGRAPHY

11.1 NORTH AMERICA

11.1.1 U.S.
11.1.2 CANADA
11.1.3 MEXICO

12 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

13 COMPANY PROFILES

13.1 ASTRAZENECA

13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 GEOGRAPHICAL PRESENCE
13.1.4 PRODUCT PORTFOLIO (PIPELINE)
13.1.5 RECENT DEVELOPMENTS

13.2 F. HOFFMANN-LA ROCHE LTD

13.2.1 COMPANY SNAPSHOT
13.2.2 REVENEUE ANALYSIS
13.2.3 GEOGRAPHICAL PRESENCE
13.2.4 PRODUCT PORTFOLIO
13.2.5 RECENT DEVELOPMENTS

13.3 NOVARTIS AG

13.3.1 COMPANY SNAPSHOT
13.3.2 REVENEUE ANALYSIS
13.3.3 GEOGRAPHICAL PRESENCE
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENTS

13.4 PFIZER INC.

13.4.1 COMPANY SNAPSHOT
13.4.2 REVENEUE ANALYSIS
13.4.3 GEOGRAPHICAL PRESENCE
13.4.4 PRODUCT PORTFOLIO
13.4.5 RECENT DEVELOPMENTS

13.5 ABBVIE INC.

13.5.1 COMPANY SNAPSHOT
13.5.2 REVENEUE ANALYSIS
13.5.3 GEOGRAPHICAL PRESENCE
13.5.4 PRODUCT PORTFOLIO
13.5.5 RECENT DEVELOPMENTS

13.6 ACTIVE BIOTECH AB.

13.6.1 COMPANY OVERVIEW
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENT

13.7 ALLERGAN

13.7.1 COMPANY SNAPSHOT
13.7.2 REVENEUE ANALYSIS
13.7.3 GEOGRAPHICAL PRESENCE
13.7.4 PRODUCT PORTFOLIO
13.7.5 RECENT DEVELOPMENTS

13.8 ARGENTIS PHARMACEUTICALS, LLC.

13.8.1 COMPANY OVERVIEW
13.8.2 PRODUCT PORTFOLIO
13.8.3 RECENT DEVELOPMENTS

13.9 BRISTOL-MYERS SQUIBB COMPANY

13.9.1 COMPANY OVERVIEW
13.9.2 REVENUE ANALYSIS
13.9.3 GEOGRAPHICAL PRESENCE
13.9.4 PRODUCTS PORTFOLIO
13.9.5 RECENT DEVELOPMENTS

13.10 DAVAL INTERNATIONAL LIMITED

13.10.1 COMPANY SNAPSHOT
13.10.2 GEOGRAPHICAL PRESENCE
13.10.3 PRODUCT PORTFOLIO
13.10.4 RECENT DEVELOPMENT

13.11 GLAXOSMITHKLINE PLC.

13.11.1 COMPANY OVERVIEW
13.11.2 REVENUE ANALYSIS
13.11.3 GEOGRAPHICAL PRESENCE
13.11.4 PRODUCTS PORTFOLIO (PIPELINE DEVELOPMENT)
13.11.5 RECENT DEVELOPMENT

13.12 JOHNSON & JOHNSON SERVICES, INC.

13.12.1 COMPANY OVERVIEW
13.12.2 REVENUE ANALYSIS
13.12.3 GEOGRAPHICAL PRESENCE
13.12.4 PRODUCT PORTFOLIO (PIPELINE)
13.12.5 RECENT DEVELOPMENTS

13.13 SANOFI

13.13.1 COMPANY SNAPSHOT
13.13.2 REVENEUE ANALYSIS
13.13.3 GEOGRAPHICAL PRESENCE
13.13.4 PRODUCT PORTFOLIO
13.13.5 RECENT DEVELOPMENT

13.14 VIDA THERAPEUTICS INC.

13.14.1 COMPANY OVERVIEW
13.14.2 PRODUCT PORTFOLIO
13.14.3 RECENT DEVELOPMENTS

14 QUESTIONNAIRE

15 RELATED REPORTS

LIST OF TABLES NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET

TABLE 1 INSIGHTS ABOUT CLINICAL TRIAL PHASES OF VARIOUS DRUGS

TABLE 2 INCIDENCE AND PREVALENCE IN PAST DECADE (REGION)

TABLE 3 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 4 NORTH AMERICA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY REGION 2017-2026 (USD MILLION)

TABLE 5 NORTH AMERICA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 6 NORTH AMERICA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY REGION 2017-2026 (USD MILLION)

TABLE 7 NORTH AMERICA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 8 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)

TABLE 9 NORTH AMERICA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 10 NORTH AMERICA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 11 NORTH AMERICA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 12 NORTH AMERICA SURGICAL TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY REGION 2017-2026 (USD MILLION)

TABLE 13 NORTH AMERICA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 14 NORTH AMERICA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)

TABLE 15 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 16 NORTH AMERICA HOSPITAL IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 17 NORTH AMERICA SPECIALTY CLINICS IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 18 NORTH AMERICA HOMECARE SETTINGS IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 19 NORTH AMERICA OTHERS IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 20 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY COUNTRY, 2017-2026 (USD MILLION)

TABLE 21 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 22 NORTH AMERICA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 23 NORTH AMERICA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 24 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)

TABLE 25 NORTH AMERICA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 26 NORTH AMERICA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 27 NORTH AMERICA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)

TABLE 28 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 29 U.S. SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 30 U.S. LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 31 U.S. SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 32 U.S. SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)

TABLE 33 U.S. DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 34 U.S. DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 35 U.S. THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)

TABLE 36 U.S. SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 37 CANADA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 38 CANADA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 39 CANADA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 40 CANADA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)

TABLE 41 CANADA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 42 CANADA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 43 CANADA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)

TABLE 44 CANADA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 45 MEXICO SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 46 MEXICO LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 47 MEXICO SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 48 MEXICO SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)

TABLE 49 MEXICO DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 50 MEXICO DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 51 MEXICO THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)

TABLE 52 MEXICO SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)

LIST OF FIGURES NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET

FIGURE 1 BELOW IS THE SCLERODERMA MAP DEFINING THE TYPES

FIGURE 2 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: SEGMENTATION

FIGURE 3 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: DATA TRIANGULATION

FIGURE 4 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: DROC ANALYSIS

FIGURE 5 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 6 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 7 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET

FIGURE 10 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET AND ESTIMATED TO BE INCREASING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD FROM 2019 TO 2026

FIGURE 11 RISING CASES OF SCLERODERMA, INCREASING ACCESS TO MEDICAL INSURANCE IN THE U.S., INCREASING MERGER AND ACQUISITIONS IS EXPECTED TO DRIVE THE NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET IN THE FORECAST PERIOD 2019 TO 2026

FIGURE 12 SYSTEMIC SCLERODERMA IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET IN 2019 & 2026

FIGURE 13 NORTH AMERICA IS THE MAXIMUM GROWING AND MOST PROFI REVENUE POCKETS FOR NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET IN THE FORECAST PERIOD FROM 2019 TO 2026

FIGURE 14 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY TYPE , 2018

FIGURE 15 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY TREATMENT TYPE , 2018

FIGURE 16 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY END USER, 2018

FIGURE 17 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: SNAPSHOT (2018)

FIGURE 18 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2018)

FIGURE 19 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2019 & 2026)

FIGURE 20 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2018 & 2026)

FIGURE 21 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY TYPE (2019-2026)

FIGURE 22 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: COMPANY SHARE 2018 (%)

Please fill in the below form and our sales representatives will get back to you Shortly

Please fill in the below form and our sales representatives will get back to you Shortly

`